Soluble and tissue biomarkers in ankylosing spondylitis.

The study of biomarkers has become a very important field of research in spondyloarthropathy. Biomarkers are useful for different aspects of the disease such as diagnosis, assessment of disease activity and outcome, including damage. The most commonly used biomarkers in spondyloarthropathies are HLA-B27 for diagnosis and erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) for disease activity. HLA-B27 is very sensitive but has a low specificity. ESR and CRP have both low sensitivity and specificity. The introduction of new and very expensive therapies is another reason for analysis of biomarkers. Clinicians need tools to predict more accurately disease activity, disease progression and response to therapy. This article focusses on the several known and new biomarkers of promise, including markers for cartilage and bone damage, and discusses some of the problems encountered during the search and development of new biomarkers. Biomarkers, soluble and tissue-related, reflecting structural damage and disease activity, constitute a high priority for the drug discovery process and the understanding of the pathogenesis of a particular disease. The identification of relevant tools to evaluate the natural course, disease activity, treatment response and outcome of ankylosing spondylitis is of increasing relevance since the raised awareness and development of new therapeutic options. Until now these different aspects are monitored by artificial patient-centred or physician-centred constructs. Very often, their approach is indirect and is not free from disease-unrelated influences. The Outcome Measures in Rheumatology Soluble Biomarker Working Group has taken several major steps towards the development and implementation of such assessment methods. The major drawback is that these tools do not directly reflect biological and pathological processes. Serological biomarkers objectively measure different aspects of the biological and pathological process and may contribute to a major advance in the assessments of patients. The ultimate goal is the use of biomarkers in a personalised approach for disease management in clinical practice.